Clinical Research: Phase 1 - Phase 4

Clinical Research: Phase 1 - Phase 4

Rare Disease Trials: The Beginning, the Middle and the End

Speaker: Angi Robinson, Executive Director, Pediatrics and Rare Diseases, Premier Research This session includes a regulatory overview of rare diseases and orphan drug status as well as practical considerations for varying stages of the development process. Viewers will learn more about conducting successful Natural History studies and the presenters will review how to avoid common...

Clinical Research: Phase 1 - Phase 4

Measuring How Well Subjects Know and Do in CNS Trials

Central nervous system (CNS) disorders represent a major medical challenge and a significant opportunity for therapeutic innovation. Sponsors who have a clear understanding of the regulatory landscape and neuropsychological testing modalities available are poised to address critical unmet needs for the millions of people living with CNS conditions. Central nervous system (CNS) conditions, including psychiatric,...

Clinical Research: Phase 1 - Phase 4

Premier Research Names Etienne Drouet Executive Director, Oncology Europe

Premier Research Group announces the appointment of Etienne Drouet to the position of Executive Director, Oncology Europe. In this position, Mr. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology business.

Clinical Research: Phase 1 - Phase 4

Premier Research Names Susan Stansfield, Ph.D. Executive VP, Clinical Development, Strengthens Premier’s Operational Delivery on Worldwide Projects

Premier Research Group announces the appointment of Susan C. Stansfield, Ph.D. to the position of Executive Vice President, Clinical Development. In this position, Dr. Stansfield will have global responsibility for leading and developing the company’s clinical trial management services provided to the biopharmaceutical industry.